A carregar...
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...
Na minha lista:
| Publicado no: | Psoriasis (Auckl) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://ncbi.nlm.nih.gov/pubmed/31696051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S161453 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|